Amgen's most recent trend suggests a bearish bias. One trading opportunity on Amgen is a Bear Call Spread using a strike $141.00 short call and a strike $146.00 long call offers a potential 43.27% return on risk over the next 23 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $141.00 by expiration. The full premium credit of $1.51 would be kept by the premium seller. The risk of $3.49 would be incurred if the stock rose above the $146.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Amgen is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Amgen is bearish.
The RSI indicator is at 54.98 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Amgen
Biotech selloff: What to buy
Thu, 25 Sep 2014 21:17:00 GMT
Biotech selloff: What to buy
Thu, 25 Sep 2014 21:17:00 GMT
4 picks in biotech
Thu, 25 Sep 2014 18:19:44 GMT
Zacks Rank #1 Additions for Thursday
Thu, 25 Sep 2014 12:31:07 GMT
Amgen to Host Summary Webcast of Kyprolis® (carfilzomib) for Injection Data Presented at The European Society for Medical Oncology (ESMO) 2014 Congress
Wed, 24 Sep 2014 21:02:00 GMT
PR Newswire – THOUSAND OAKS, Calif., Sept. 24, 2014 /PRNewswire/ — Amgen (AMGN) and its subsidiary Onyx Pharmaceuticals, Inc. today announced that they will host a summary webcast of Kyprolis® (carfilzomib) for Injection data presented at the European Society for Medical Oncology (ESMO) 2014 Congress on Monday, Sept. 29, 2014, at 1 p.m. PT. Pablo Cagnoni, M.D., president of Onyx Pharmaceuticals, Inc., along with clinical investigators, will participate in the call. In addition, they will discuss a summary of feedback received from key opinion leaders and the steps Amgen is taking to develop Kyprolis across all lines of therapy to address unmet needs in patients with multiple myeloma. The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors.
Related Posts
Also on Market Tamer…
Follow Us on Facebook